Charles Debusk, MD
Family Medicine · New Tazewell, TNNPI 1780665745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by GSK at 37.1% of the total. Reporting peaked in 2019 at $2,102 and has fallen 98.7% since, to $28 in 2025.
Across 175 payments — averaging $29.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$935
- Novo Nordisk$625
- Johnson & Johnson$527
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$227
- Pfizer$204
- plus $677 from 18 others
Across 150 payments — averaging $1464.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$114K
- Abbott$88K
- Alnylam Pharmaceuticals Inc.$16K
- Visby Medical, Inc.$2K
What the payments were for
- Food & beverage$5,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 71 | $1,882 |
| AstraZeneca | 14 | $935 |
| Novo Nordisk | 30 | $625 |
| Johnson & Johnson | 11 | $527 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $227 |
| Pfizer | 12 | $204 |
| Mylan Specialty L.p. | 3 | $153 |
| Boehringer Ingelheim | 3 | $130 |
| AbbVie | 3 | $89 |
| Xeris Pharmaceuticals, Inc. | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $23 |
| Genentech USA, Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Corium, LLC | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Novartis | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$359
- TRELEGY ELLIPTA$336
- BREZTRI AEROSPHERE$260
- FARXIGA$249
- AREXVY$247
- Yupelri$125
- Ozempic$122
How this compares
$5,077 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 201 | $141,061 |
| OzempicSemaglutide | 75 | $98,622 |
| TradjentaLinagliptin | 93 | $79,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $64,419 |
| JanuviaSitagliptin Phosphate | 73 | $58,546 |
| TrulicityDulaglutide | 32 | $37,111 |
| XareltoRivaroxaban | 44 | $33,230 |
| EntrestoSacubitril/Valsartan | 32 | $31,281 |
| JardianceEmpagliflozin | 46 | $30,833 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $24,910 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $23,565 |
| MounjaroTirzepatide | 16 | $19,352 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $13,266 |
| BrilintaTicagrelor | 21 | $13,184 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 533 | $12,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $204 | $147,994223 claims |
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $130 | $138,736198 claims |
| Novo NordiskOzempic | $625 | $98,62275 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,882 | $89,328111 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $13 | $56,46248 claims |
| AstraZenecaBreztri Aerosphere, Brilinta, Farxiga, Symbicort | $935 | $51,05671 claims |
| Johnson & JohnsonXarelto | $527 | $33,23044 claims |
| NovartisEntresto | $14 | $31,28132 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $4,42325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in New Tazewell
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
- Curtis JantziKingsport$39K
- Ellen ClelandChattanooga$38K
- Meredith SchweitzerAntioch$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.